HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Primary angioplasty for acute myocardial infarction in the elderly.

Abstract
Elderly patients with acute myocardial infarction present a formidable therapeutic challenge. Although there appears to be a survival benefit from thrombolytic therapy for the eligible elderly patient, persistent concerns regarding the risk of intracranial hemorrhage impedes utilization in this age group. Primary or direct angioplasty of the infarct artery has been proven to be an effective modality for reperfusion. Randomized comparisons suggest an advantage over thrombolysis in terms of achieving superior patency and mitigating recurrent ischemic events. Primary angioplasty expands the reperfusion population by including many patients ineligible for thrombolysis and is more effective for treating patients at high risk, such as those with cardiogenic shock. Acute angiography accumulates important prognostic and decision-facilitating information. The benefits of primary angioplasty are more impressive for the aging patient. The survival gain and reduction in intracranial hemorrhage may combine to magnify the advantages of performing angioplasty on patients in this group. Emerging evidence concerning the aging population validates continued examination of this invasive reperfusion approach.
AuthorsG E Lane, D R Holmes Jr
JournalCoronary artery disease (Coron Artery Dis) Vol. 11 Issue 4 Pg. 305-13 (Jun 2000) ISSN: 0954-6928 [Print] England
PMID10860173 (Publication Type: Journal Article, Review)
Topics
  • Aged
  • Angioplasty, Balloon, Coronary
  • Coronary Angiography
  • Humans
  • Myocardial Infarction (complications, therapy)
  • Randomized Controlled Trials as Topic
  • Shock, Cardiogenic (complications)
  • Thrombolytic Therapy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: